

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of contents of this announcement.

This announcement appears for information only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

**LAPSE OF THE
(1) DISCLOSEABLE AND CONNECTED TRANSACTION
IN RELATION TO THE ACQUISITION OF
25% EQUITY INTEREST IN THE TARGET COMPANY
INVOLVING THE ISSUE OF CONSIDERATION SHARES
UNDER SPECIFIC MANDATE;
AND
(2) CONTINUING CONNECTED TRANSACTION**

**LAPSE OF THE SALE AND PURCHASE AGREEMENT AND THE LICENSING
AND MASTER SERVICE AGREEMENT**

Sinopharm Tech Holdings Limited (the “**Company**”) would like to provide the Shareholders and potential investors of the Company with an update of the transactions contemplated under each of the Sale and Purchase Agreement and the Licensing and Master Service Agreement. As the conditions precedent set out in the Sale and Purchase Agreement and the Licensing and Master Service Agreement have not been fully fulfilled (or as the case may be, waived) on or before the Long Stop Date on 30 June 2021, the transactions contemplated under each of the Sale and Purchase Agreement and the Licensing and Master Service Agreement have lapsed and will not proceed.

Since the Company has already contracted with clients for delivering the anti-counterfeiting devices, the Company expects that the Licensee will shortly sign a standalone agreement with the SZCo and the Company will comply with the requirements under the GEM Listing Rules.

References are made to the announcements of the Company dated 18 February 2021 (the “**Announcement**”), 17 March 2021, 31 March 2021 and 14 May 2021 respectively, in relation to (i) the discloseable and connected transaction in relation to the acquisition of 25% equity interest in Rich General Limited involving the issue of the Consideration Shares under specific mandate; and (ii) the continuing connected transaction of the Company. Terms used herein shall have the same meanings as those defined in the Announcement, unless otherwise specified.

The Company would like to provide the Shareholders and potential investors of the Company with an update of the transactions contemplated under each of the Sale and Purchase Agreement and the Licensing and Master Service Agreement. As the conditions precedent set out in the Sale and Purchase Agreement and the Licensing and Master Service Agreement have not been fully fulfilled (or as the case may be, waived) on or before the Long Stop Date on 30 June 2021, the transactions contemplated under each of the Sale and Purchase Agreement and the Licensing and Master Service Agreement have lapsed and will not proceed. The Sale and Purchase Agreement shall cease and determine and neither party shall have any obligations and liabilities towards each other hereunder save for any antecedent breaches of the terms hereof. The Licensing and Master Service Agreement shall automatically terminate and none of the parties thereto shall have any claims against each other.

Since the Company has already contracted with clients for delivering the anti-counterfeiting devices, the Company expects that the Licensee will shortly sign a standalone agreement with the SZCo and the Company will comply with the requirements under the GEM Listing Rules. The Board is of the view that the lapse of the transactions contemplated under each of the Sale and Purchase Agreement and the Licensing and Master Service Agreement will not have any material adverse effect on the financial position and business operations of the Group.

By Order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Chairperson

Hong Kong, 2 July 2021

As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.